Completion of Acquisition
Completion of Acquisition of Italian service company
Further to the announcement made on 27 May 2009, Cryo-Save Group N.V. (AIM: CRYO, “Cryo-Save” or “the Group”), Europe’s leading stem cell bank, is pleased to announce the completion of the acquistion of Salus Futura Ltd, which holds all shares of Salus Futura Srl, Italy (“Salus Futura”), following the signing of the sale and purchase agreement and transfer of the initial consideration of €0.4 million in return for Salus Futura shares on 10 July 2009.
For further details
+ 31 (0) 575 548998
Arnoud van Tulder, Chief Financial Officer
Daniel Stewart & Company plc
+ 44 (0) 20 7776 6550
Simon Leathers/Charlotte Stranner
+ 44 (0) 20 7457 2020
Adrian Duffield/Rozi Morris
With more than 100,000 samples saved, Cryo-Save is the leading stem cell bank in Europe and one of the fastest growing in the world. Driven by its international business strategy, Cryo-Save is now represented in 38 countries on three continents and has state-of-the-art processing facilities in Belgium, Germany, Dubai, India and France (under construction). Cryo-Save sets the highest quality standards in stem cell storage, as it aims to make an important contribution to conquer possible life-threatening diseases in the future. As a service to the public, Cryo-Save offers a Cost-free Family Donation Programme, free of charge, to families wishing to store their newborn’s umbilical cord blood stem cells for a family member diagnosed with a life-threatening disease treatable by stem cells. The company is committed to further improve stem cell cryopreservation techniques, by participating in European Commission funded projects, in Universities and Hospitals.